Can Cemiplimab be used to treat small cell lung cancer?

Cemiplimab (Cemiplimab) is an immunotherapy drug that acts as a PD-1 inhibitor and helps the body recognize and attack cancer cells by enhancing the immune system. The drug is currently mainly used to treat cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) and non-small cell lung cancer (NSCLC). These cancer types have high immune evasion properties, so the use of immune checkpoint inhibitors can effectively improve the effectiveness of treatment.

For small cell lung cancer (SCLC), although the clinical application of cimepilimab has mainly focused on cutaneous squamous cell carcinoma and non-small cell lung cancer, the potential of immune checkpoint inhibitors in SCLC has also been studied. In the treatment of small cell lung cancer, some immunotherapy drugs have been approved, such as pembrolizumab (Pembrolizumab) and atezolizumab (Atezolizumab). These drugs enhance the anti-cancer ability of the immune system by inhibiting the PD-1 or PD-L1 pathways, and have shown certain clinical benefits especially in the combined treatment of small cell lung cancer.

Although there is no extensive clinical data or approval for the use of cimipilimab in small cell lung cancer, cimepilimab may theoretically have some therapeutic potential as immune checkpoint inhibitors have shown positive results in other types of lung cancer. However, there is currently no clear clinical evidence that cimepilimab can effectively treat small cell lung cancer. Therefore, for patients with small cell lung cancer, choosing other approved immunotherapy drugs or conventional treatment is still a more recommended option.

In general, although cimepilimab has shown good efficacy in cancer types such as cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer, there is currently insufficient evidence to support its widespread use in the treatment of small cell lung cancer.

Reference materials: https://www.libtayohcp.com/